Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-02-27
1999-06-29
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514419, 514438, 548496, 549 76, A61K 3800, A61K 3140, A61K 3138, C07D33322
Patent
active
059168781
ABSTRACT:
Synthetic immunomodulatory molecules having a .gamma.-L-glutamyl-, a .gamma.-D-glutamyl, a .beta.-L-aspartyl, or a .beta.-D-aspartyl moiety at the amino terminus are provided as illustrated by Formula A. In Formula A, "n" is 1 or 2, R is hydrogen, acyl or alkyl, and X is an aromatic or heterocyclic amino acid or its derivative. A particularly preferred embodiment is .gamma.-D-glutamyl-L-tryptophan, which has immunomodulatory activity.
REFERENCES:
patent: 4125626 (1978-11-01), Orlowski et al.
patent: 4568489 (1986-02-01), Floyd
patent: 4758551 (1988-07-01), Meister et al.
patent: 5206220 (1993-04-01), Hilton
patent: 5736519 (1998-04-01), Deigin et al.
patent: 5744452 (1998-04-01), Kolobov et al.
Christian, J.S., "A Review of the Pharmacology, Clinical Applications, and Toxicology of Thymopentin," Transgenica: The Journal of Clinical Biotechnology, 1, pp. 23-34 (1994).
Prezioso et al., ".gamma.-Glutamyltraspeptidase Expression Regulates the Growth-Inhibitory Activity of the Anti-Tumor Prodrug .gamma.-L-glutaminyl-4-hydroxy-3-iodobenzene," Int. J. Cancer, 56, pp. 874-879 (1994).
Li Kam Wa et al., "The Antiatriuretic Action of .gamma.-L-glutamyl-5-hydroxy-L-tryptophan is Dependent on its Decarboxylation to 5-hydroxytryptamine in Normal Man," Br. J. Clin. Pharmac., 387, pp. 265-269 (1994).
Illum, Lisbeth, "The Nasal Delivery of Peptides and Proteins," Trends in Biotechnology, 9, pp. 284-289 (1991).
Goldstein et al., "Thymopoietin to Thymopentin: Experimental Studies," Thymopentin in Experimental and Clinical Medicine, Survey of Immunologic Research, 4, Supp. 1, pp. 1-10 (1985).
Gillis et al., "T-Cell Growth Factor: Parameters of Production and Quantitative Assay for Activity," J. Immunol., 120:6, pp. 2027-2032 (1978).
Wellner, Daniel, "Separation of .gamma.-Glutamyl Amino Acids by Ion-Exchange Chromatography," Methods in Enzymology, 113, pp. 564-566, 1985.
Hirata et al., "Studies on Separation of Amino Acids and Related Compounds. VIII. Separation of L-Aspartyl-(.alpha.,.beta.)-L-histidine and of L-Glutamyl-(.alpha.,.gamma.)-L-Histidine," Bulletin of the Chemical Society of Japan, 45, pp. 1790-1794, 1972.
Hasegawa et al., ".gamma.-Glutamylpeptide Formative Activity of Corynebacterium glutamicum by the Reverse Reaction of the .gamma.-Glutamylpeptide Hydrolytic Enzyme," Agric. Biol. Chem., 42:2, pp. 371-381, 1978.
Greene and Wuts, "Carbamates" in chapter entitled "Protection for Imidazoles, Pyrroles, and Indoles" from Protective Groups in Organic Synthesis, New York: John Wiley & Sons, Inc., p. 387, 1991.
Kolobov Alexander A.
Simbirtsev Andrey S.
Lambkin Deborah C.
Wei Edward T.
LandOfFree
.gamma.-glutamyl and .beta.-aspartyl containing immunomodulator does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with .gamma.-glutamyl and .beta.-aspartyl containing immunomodulator , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and .gamma.-glutamyl and .beta.-aspartyl containing immunomodulator will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375523